Organon will present a new real-world analysis of VTAMA® (tapinarof) cream, 1%, at the 2026 Fall Clinical Dermatology Conference, according to an announcement distributed via biospace.com.

The presentation will add real-world evidence to the clinical profile of tapinarof, a non-steroidal topical aryl hydrocarbon receptor agonist that Organon markets for dermatologic use. For clinicians, real-world analyses matter because they show how a therapy performs across routine practice populations — broader, less selected than randomized trial cohorts.

What does the announcement cover?

• Product: VTAMA® (tapinarof) cream, 1%, a topical non-steroidal treatment.
• Data type: A new real-world analysis, rather than pivotal trial results.
• Venue: The 2026 Fall Clinical Dermatology Conference, a recurring dermatology meeting held each fall in Las Vegas.
• Sponsor: Organon, which holds commercial rights to the product.

The announcement itself, as carried by biospace.com, did not specify the exact indications studied, the size of the real-world cohort, or the endpoints measured. Those details are expected to accompany the conference presentation itself.

Why real-world data draw attention

Regulatory approvals and phase 3 programs establish efficacy under controlled conditions. Real-world analyses test whether those results hold in everyday clinics, where adherence, comorbidities and treatment switching complicate the picture.

For a topical agent, real-world evidence typically informs practical questions:

• How long patients continue therapy in routine care
• Response patterns outside trial inclusion criteria
• Tolerability in broader age and severity ranges

Organon's decision to bring this analysis to a dermatology-focused audience signals the company's intent to build the evidence base for tapinarof beyond its registrational program.

What to watch at the meeting

Attendees at the 2026 Fall Clinical Dermatology Conference can expect the presentation to clarify the analysis population, comparator context if any, and durability findings. Poster or podium disclosure would also address how the real-world results align with what controlled trials previously reported for the cream.

Full details — including the analysis design, cohort characteristics and outcome measures — remain pending until the data are formally presented at the conference.